HAVCR2 and cancer: The patients with stage I/II cancer contained the mildly increased percentage of Tim-3+PD-1+CD8+ T cells which did not reach the statistical significance when compared with HDs (median 1.74% vs 1.99%, p = 0.6860, Figure 6A).